The treatment of multiple myeloma (MM) continues to evolve rapidly with arrival of multiple
new drugs, and emerging data from randomized trials to guide therapy. Along the disease …

Summary This Policy Review presents the International Myeloma Working Group's clinical
practice recommendations for the treatment of relapsed and refractory multiple myeloma …

Background Ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)–
directed CAR T-cell therapy, is effective in heavily pretreated patients with relapsed or …

Background Lenalidomide and bortezomib frontline exposure has raised a growing need for
novel treatments for patients with relapsed or refractory multiple myeloma. Carfilzomib in …

Background Isatuximab is a monoclonal antibody that binds a specific epitope on the human
CD38 receptor and has antitumour activity via multiple mechanisms of action. In a previous …

Since the publication of the article entitled “Multiple Myeloma: EHA-ESMO Clinical Practice
Guidelines for Diagnosis, Treatment and Follow-up”(HemaSphere. 2021; 5: e528) …

Cancer therapies often have narrow therapeutic indexes and involve potentially suboptimal
combinations due to the dissimilar physical properties of drug molecules. Nanomedicine …

Multiple myeloma (MM) accounts for 1% of all cancers and $10% of all haematological
malignancies. The incidence in Europe is 4.5–6.0/100 000/year with a median age at …

The treatment of relapsed/refractory multiple myeloma (MM) has evolved to include several
new options. These include new combinations with second generation proteasome …

Longer-term outcomes with the anti-CD38 antibody isatuximab in combination with
carfilzomib-dexamethasone (Isa-Kd) were evaluated in the randomized Phase 3 trial IKEMA …